Neurocrine Biosciences, Inc. · NASDAQ:NBIX
Neurocrine Biosciences — Q4 2022 Earnings Presentation
42 slides from Neurocrine Biosciences's earnings presentation, Feb 6, 2023
Slide 1: Advancing Life-Changing Discoveries in Neuroscience
Advancing Life-Changing Discoveries in Neuroscience Q4 2022 / Year-End Corporate Presentation February 6, 2023 Nasdaq: NBIX
Slide 2: Safe Harbor Statement and Non-GAAP Financial Measures
Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our
Slide 3: Well Positioned for Sustained & Long-term Growth
Well Positioned for Sustained & Long-term Growth 2023 Annual Net * Sales Guidance of ~600,000 are affected by TD in the U.S. $1.67B to $1.77B (70% are undiagnosed) (Tardive Dyskinesia Only) R&D Focus Robust 12 Programs Currently in Mid- to Late-Stage Studies • Neurology • Neuroendocrinology Pipeline
Slide 4: Q4 & FY 2022 Highlights and Future Key Milestones and Activities
Q4 & FY 2022 Highlights and Future Key Milestones and Activities Q4 2022 and FY Highlights Future Key Milestones and Activities ▪ INGREZZA® (valbenazine) Net Product Sales of over $1.4B with 2023 ~ 260,000 TRx in 2022 ▪ Potential sNDA Approval of Valbenazine for the Treatment of − Represents YoY Sal
Slide 5: Significant Milestones This Year
Significant Milestones This Year Valbenazine Crinecerfont NBI-921352 NBI-1065846 Chorea in HD Congenital Adrenal Hyperplasia Focal Onset Seizures Anhedonia in MDD PDUFA = August 20th Phase 3 data in Adult and Phase 2 data Phase 2 data Pediatric Studies Selective CRF1 receptor Selective Nav channel G
Slide 6: Multiple Molecules and Mechanisms to Treat Intractable Diseases
Multiple Molecules and Mechanisms to Treat Intractable Diseases NEUROLOGY NEUROENDOCRINOLOGY SCN8A Chorea in Tardive Focal Onset Developmental Adrenal Huntington Dyskinesia Parkinson’s Endometriosis Uterine Fibroids Insufficiency Seizures (FOS) and Epileptic Disease (HD) Disease FDA APPROVED FDA APP
Slide 7: Strong Pipeline Momentum
Strong Pipeline Momentum Phase 1 Phase 2 Phase 3 Partner Upcoming Milestones Neurology valbenazine* Chorea in Huntington Disease PDUFA Date = August 20th, 2023 valbenazine* Dyskinetic Cerebral Palsy Registrational Top-Line Data Expected in 2024 Reviewing Full Data Set from Phase 2 Study to NBI-82710
Slide 8: 2022 Annual Financial Summary
2022 Annual Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item 2022 2021 Highlights / Comments Revenue $1,489 $1,133 - Product Sales, Net 1,441 1,090 INGREZZA Sales of ~$1.43 Billion - Collaboration Revenue 48 43 Non-GAAP R&D Expense 406 280 Increase Driven by Expanded / Advancing
Slide 9: Q4 2022 Financial Summary
Q4 2022 Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item Q4 2022 Q4 2021 Highlights / Comments Revenue $412 $312 Q4 2022 INGREZZA Sales of $399M with Record - Product Sales, Net 405 304 New Patients and Continued Strong Compliance / Persistence Rates for Existing Patients - Coll
Slide 10: 2023 INGREZZA Sales and Operating Expense Guidance
2023 INGREZZA Sales (TD Indication Only) and Operating Expense Guidance Item ($ Millions) 2022 Actuals 2023 Guidance Range INGREZZA Net Product Sales1 $1,428 $1,670 - $1,770 GAAP R&D Expense2 $464 $550 - $580 Non-GAAP R&D Expense3 $406 $495 - $525 GAAP SG&A Expense $753 $850 - $870 Non-GAAP SG&A Exp
Slide 11: Corporate Sustainability
Corporate Sustainability Our Purpose: Relieve Suffering for People with Great Needs, but Few Options Adhere to the highest Invest in our people Minimize our impact product quality and and communities on the environment safety standards Comprehensive Quality Industry-leading employee Improving profit
Slide 12: Our Medicines, Our Patients
© NEYROCRINE Our Medicines, Our Patients
Slide 13: Commercial Products Fueling Pipeline Investment
Commercial Products Fueling Pipeline Investment In the U.S. * ‡ And now… TARDIVE DYSKINESIA ENDOMETRIOSIS For pediatric patients in the ‡ U.S. and EU † ADRENAL INSUFFICIENCY PARKINSON'S DISEASE UTERINE FIBROIDS *Mitsubishi Tanabe Pharma Corporation (MTPC) has commercialization rights in Japan and ot
Slide 14: INGREZZA
INGREZZA (valbenazine) capsules NEUROCRINE BIOSCIENCES
Slide 15: INGREZZA Quarterly Net Sales Performance
INGREZZA Quarterly Net Sales Performance ($MM) $450 7th Sequential Period of Growth $399 $400 $376 $350 $350 $301 $303 $300 $287 $265 $250 $230 $200 Q1 '21 Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 Q3 '22 Q4 '22 15
Slide 16: Substantial Impact on TD Patients and Care Partners
Substantial Impact on TD Patients and Care Partners Movement disorder caused by prolonged use of antipsychotics and anti-nausea medications Uncontrollable, abnormal and repetitive movements >50% of patients experience meaningful emotional, social and psychological impact* Job Performance Low Self-Wo
Slide 17: Nascent TD Market Presents Significant Opportunity
Nascent TD Market Presents Significant Opportunity Approximately 30% of TD Patients Diagnosed E S T I M AT E D T O A F F E C T ~600,000 ✓ Only half of diagnosed patients receive treatment for TD with a VMAT2 inhibitor like INGREZZA people in the U.S. ~30% TD Diagnosed Increasing Antipsychotic Prescr
Slide 18: Driving Long-Term Growth for INGREZZA
Driving Long-Term Growth for INGREZZA Salesforce and distribution expansion INGREZZA and ONGENTYS offering greater access to neurology practices Investing in telemedicine capabilities Recommends patients with TD associated with antipsychotic therapy be treated with a VMAT2 inhibitor Patient outreach
Slide 19: ONGENTYS Is the 1st and Only FDA-Approved Once-Daily COMT Inhibitor
ONGENTYS Is the 1st and Only FDA-Approved Once-Daily COMT Inhibitor for Parkinson’s Disease Provides Significant Reduction of Daily “Off” Time; Increase in Good “On” Time • Add-on treatment to levodopa/carbidopa prolongs clinical effects • One capsule, once a day treatment • Helps patients achieve m
Slide 20: Neurology Pipeline
© NEVROCRINE Neurology Pipeline
Slide 21: sNDA for Valbenazine for Chorea in Huntington Disease Accepted by FDA
Supplemental New Drug Application for Valbenazine for the Treatment of Chorea in Huntington Disease Accepted by FDA Valbenazine* Simple once-a-day treatment targeted for symptom control of chorea movements Safety profile consistent with and supported by extensive safety data in tardive dyskinesia In
Slide 22: Valbenazine: Registrational Program in Dyskinetic Cerebral Palsy
Valbenazine*: Registrational Program in Dyskinetic Cerebral Palsy Dyskinetic Cerebral Palsy (DCP) A form of cerebral palsy (CP) that affects ~15% of the approximately 500,000 to 1M people in the U.S. diagnosed with the disease. Can result in a range of developmental delays, physical difficulties and
Slide 23: NBI-921352: Selective Nav1.6 Inhibitor in Ongoing Phase 2 Studies
NBI-921352*: Selective Nav 1.6 Inhibitor in Ongoing Phase 2 Studies With Top-Line Data Expected in FOS in 2H 2023 Adult Focal Onset Seizures (FOS) Background SCN8A-DEE Background Also referred to as partial-onset seizures, Rare pediatric epilepsy with occurrence of these are the most common form of
Slide 24: Neuroendocrinology Pipeline
Neuroendocrinology Pipeline
Slide 25: Classic Congenital Adrenal Hyperplasia (CAH)
Classic Congenital Adrenal Hyperplasia (CAH) Rare Genetic Disorder Enzyme deficiency & reduced cortisol levels and excess androgen levels U.S. ~30,000* Europe ~50,000* Complex and Treatment Options Highly Stagnant for 60 Years Variable • Hormone replacement Symptoms • Do not address underlying issue
Slide 26: Congenital Adrenal Hyperplasia Disease Mechanism
Congenital Adrenal Hyperplasia Disease Mechanism Normal Homeostasis CAH Patients 26
Slide 27: Crinecerfont Potentially Meets Challenges of the Standard of Care
Crinecerfont* Potentially Meets Challenges of the Standard of Care Overtreatment Hypercortisolism Overtreatment Insulin Resistance Undertreatment Hypercortisolism Central Obesity Hyperandrogenism Osteoporosis Potentially Fatal Adrenal Crisis Insulin Resistance Impaired Glucose Tolerance CRINECERFONT
Slide 28: Potential Paradigm Shift in the Treatment of CAH
Potential Paradigm Shift in the Treatment of CAH With Top-Line Results Expected For Each Study in 2H 2023 Crinecerfont* Phase 3 Global Adult Registrational Study Ongoing ENROLLMENT Phase 3 Global Pediatric Registrational Study Ongoing COMPLETE Potent Orally Active Selective Well-Tolerated *Crinecerf
Slide 29: Neuropsychiatry Pipeline
(5) NEUROCRINE BIOSCIENCES
Slide 30: Valbenazine: Registrational Program in Adjunctive Treatment of Schizophrenia
Valbenazine*: Registrational Program in Adjunctive Treatment of Schizophrenia With Top-Line Date in 1st Study in 2024 Adjunctive Treatment of Schizophrenia (ATS) Schizophrenia is one of the leading causes of disability worldwide, affecting up to 3.5M people in the U.S. alone. A serious, chronic ment
Slide 31: Potential First-in-Class Neuropsychiatry Programs
Potential First-in-Class Neuropsychiatry Programs Takeda Collaborations Ongoing Clinical Programs in Phase 2 Studies Clinical Programs in Phase 2 Studies NBI-1065846* Anhedonia in Major Depressive Disorder Top-line Data Expected in 2H 2023 Inadequate Response to Treatment in NBI-1065845* Major Depre
Slide 32: NBI-1065846: GPR139 Agonist
NBI-1065846*: GPR139 Agonist Anhedonia in Major Depressive Disorder NBI-1065846 260 million+ people worldwide are Potent first-in-class investigational GPR139 agonist • Once weekly affected by major depressive disorder • Potential adjunctive treatment (MDD). GPR139 is an orphan receptor in the haben
Slide 33: NBI-1065845: AMPA Potentiator
NBI-1065845*: AMPA Potentiator Inadequate Response to Treatment NBI-1065845 in Major Depressive Disorder (MDD) Potent first-in-class AMPA potentiator ~1/3 of the 16 million+ people in the • Once daily U.S. who live with MDD do not respond • Potential adjunctive treatment to available antidepressants
Slide 34: Luvadaxistat: D-Amino Acid Oxidase (DAAO) Inhibitor
Luvadaxistat*: D-Amino Acid Oxidase (DAAO) Inhibitor Cognitive Impairment Associated with Luvadaxistat Schizophrenia (CIAS) Affects approximately 80% of the 3.5 Potent first-in-class DAAO inhibitor • Once daily million people in the U.S. diagnosed • No titration requirement with schizophrenia Hypofu
Slide 35: Developing Novel Muscarinic Receptor Agonist Portfolio
Developing Novel Muscarinic Receptor Agonist Portfolio Neurocrine Biosciences Advancing Muscarinic Portfolio Clinical studies, include: ➢ Initiated Phase 2 placebo-controlled study of NBI-1117568*, a selective M4 agonist, as a potential treatment for schizophrenia ✓ NBI-1117568 offers the potential
Slide 36: Well Positioned for Sustained & Long-term Growth
Well Positioned for Sustained & Long-term Growth 2023 Annual Net * Sales Guidance of ~600,000 are affected by TD in the U.S. $1.67B to $1.77B (70% are undiagnosed) (Tardive Dyskinesia Only) R&D Focus Robust 12 Programs Currently in Mid- to Late-Stage Studies • Neurology • Neuroendocrinology Pipeline
Slide 37: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations neurocrine.com
Slide 38: Condensed Consolidated Statements of Operations
NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data) Revenues: Product sales, net Collaboration revenue Total revenues Operating expenses: Cost of revenues Research and development Acquired in-process research and de
Slide 39: Condensed Consolidated Balance Sheets
NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) December 31, December 31, (in millions) 2022 2021 Cash, cash equivalents and debt securities available-for-sale $ 989.3 $ 711.3 Other current assets 464.2 261.5 Total current assets 1,453.5 972.8 Deferred tax assets 305.9
Slide 40: Reconciliation of GAAP to Non-GAAP Financial Results
NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS (unaudited) Three Months Ended Twelve Months Ended December 31, December 31, (Gn millions, except per share data) 2022 2021 2022 2021 GAAP net income (loss) $ $90 $ (73) $1545 $ 39.6 Adjustments:
Slide 41: Reconciliation of GAAP to Non-GAAP Expenses
NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP EXPENSES (unaudited) Three Months Ended ‘Twelve Months Ended December 31, December 31, (x millions) 2022 2021 2032 2021 GAAP cost of revenues $ 77 $ 41 $ 232 $ 143 Adjustments: Non-cash amortization related to acq
Slide 42: Advancing Life-Changing Discoveries in Neuroscience
Advancing Life-Changing Discoveries in Neuroscience Q4 2022 / Year-End Corporate Presentation February 6, 2023 Nasdaq: NBIX
Neurocrine Biosciences — Q4 2022 Earnings Presentation on 6ix